Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut, United States
Dr. Hurwitz is associate professor of medicine in the division of medical oncology at the Yale University School of Medicine and co-leader of the Cell Therapies Clinical Research Team and Assistant Director of Education for the Yale Cancer Center. He attends in the Smilow Cancer Hospital/Yale Cancer Center. He specializes in the use of immune cell-based therapies. His research focuses on translational studies and clinical trials in these malignancies. Specific studies include analyses of immune cell expression profiles during ex vivo growth, immune cell infiltration in tumors and trials of novel agents, particularly adoptive cell and CAR-T therapies. He has been involved in multiple trials using immune cells as therapeutic agents. These include trials of tumor infiltrating lymphocytes (TIL) and of CAR-T and other engineered cells in various solid tumors.
Disclosure(s): Contract Research: achilles therapeutics (Ongoing); CRISPR Therapeutics (Ongoing); Iovance (Ongoing)
Non-CE Consulting: affini-T (Terminated, June 3, 2023); CRISPR Therapeutics (Terminated, June 3, 2023); Exelixis (Terminated, June 3, 2023); Janssen (Terminated, June 3, 2023); Pliant Therapeutics (Terminated, June 3, 2023); Regeneron (Terminated, June 3, 2023); Tscan (Terminated, June 3, 2023)